Laura B. Goddard

Array ( [id] => 13929137 [patent_doc_number] => 20190048084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS [patent_app_type] => utility [patent_app_number] => 16/053540 [patent_app_country] => US [patent_app_date] => 2018-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16053540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13609745 [patent_doc_number] => 20180356422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => Methods and Diagnostics for Cancer Detection and Treatment Monitoring [patent_app_type] => utility [patent_app_number] => 16/048607 [patent_app_country] => US [patent_app_date] => 2018-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16048607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735682 [patent_doc_number] => 10961318 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Anti-SIRP-a antibodies and related methods [patent_app_type] => utility [patent_app_number] => 16/045312 [patent_app_country] => US [patent_app_date] => 2018-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 27705 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16459529 [patent_doc_number] => 10842857 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Vaccines against an oncogenic isoform of HER2 (ErbB2) and methods of using the same [patent_app_type] => utility [patent_app_number] => 16/045248 [patent_app_country] => US [patent_app_date] => 2018-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 7757 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16459527 [patent_doc_number] => 10842855 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Vaccines against an oncogenic isoform of ESR1 and methods of using the same [patent_app_type] => utility [patent_app_number] => 16/044269 [patent_app_country] => US [patent_app_date] => 2018-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 8037 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16044269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13960117 [patent_doc_number] => 20190056402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => ORGAN SPECIFIC DIAGNOSTIC PANELS AND METHODS FOR IDENTIFICATION OF ORGAN SPECIFIC PANEL PROTEINS [patent_app_type] => utility [patent_app_number] => 16/042645 [patent_app_country] => US [patent_app_date] => 2018-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16042645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590047 [patent_doc_number] => 20180346572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS [patent_app_type] => utility [patent_app_number] => 16/029352 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14519121 [patent_doc_number] => 10336807 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-02 [patent_title] => Chimeric proteins and methods of immunotherapy [patent_app_type] => utility [patent_app_number] => 16/029299 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 192 [patent_no_of_words] => 77986 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 254 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461773 [patent_doc_number] => 20180282429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => Bispecific Antigen-Binding Constructs Targeting HER2 [patent_app_type] => utility [patent_app_number] => 16/011048 [patent_app_country] => US [patent_app_date] => 2018-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16011048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15873001 [patent_doc_number] => 20200143904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => PREDICTING MOLECULAR PROPERTIES OF MOLECULAR VARIANTS USING RESIDUE-SPECIFIC MOLECULAR STRUCTURAL FEATURES [patent_app_type] => utility [patent_app_number] => 16/620389 [patent_app_country] => US [patent_app_date] => 2018-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738333 [patent_doc_number] => 12215151 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 [patent_app_type] => utility [patent_app_number] => 16/618050 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 33 [patent_no_of_words] => 100349 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733199 [patent_doc_number] => 20180371067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG4-5 [patent_app_type] => utility [patent_app_number] => 15/991998 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15978559 [patent_doc_number] => 10669589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments [patent_app_type] => utility [patent_app_number] => 15/981514 [patent_app_country] => US [patent_app_date] => 2018-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 29 [patent_no_of_words] => 42731 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15981514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650007 [patent_doc_number] => 10927170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma [patent_app_type] => utility [patent_app_number] => 15/979609 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 32 [patent_no_of_words] => 17274 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236941 [patent_doc_number] => 11180813 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization [patent_app_type] => utility [patent_app_number] => 15/977258 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 30084 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15977258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16499870 [patent_doc_number] => 10865245 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Anti-B7H3 binding compounds and uses thereof [patent_app_type] => utility [patent_app_number] => 15/967858 [patent_app_country] => US [patent_app_date] => 2018-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 20194 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15967858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15696809 [patent_doc_number] => 10604572 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Antibody to human and mouse Sema3A and use thereof [patent_app_type] => utility [patent_app_number] => 15/964648 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 37 [patent_no_of_words] => 8122 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15696807 [patent_doc_number] => 10604571 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Antibody to human and mouse SEMA3A and use thereof [patent_app_type] => utility [patent_app_number] => 15/964463 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 37 [patent_no_of_words] => 8088 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13387093 [patent_doc_number] => 20180245088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => Antibody To Be Cross-Linked To Human SEMA3A And Use Thereof [patent_app_type] => utility [patent_app_number] => 15/964763 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460785 [patent_doc_number] => 10844120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Humanized antigen-binding domains and methods of use [patent_app_type] => utility [patent_app_number] => 15/961562 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 27 [patent_no_of_words] => 25754 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15961562 [rel_patent_id] =>[rel_patent_doc_number] =>)